Nutex Health (NASDAQ:NUTX - Get Free Report) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.
Several other research analysts have also commented on NUTX. B. Riley Financial assumed coverage on Nutex Health in a research report on Friday, June 26th. They issued a "buy" rating and a $290.00 target price for the company. Wall Street Zen downgraded shares of Nutex Health from a "strong-buy" rating to a "buy" rating in a report on Monday, July 20th. Lake Street Capital restated a "buy" rating and issued a $310.00 price target (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded Nutex Health from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $300.00.
Check Out Our Latest Report on Nutex Health
Nutex Health Trading Up 0.3%
NUTX opened at $188.10 on Monday. Nutex Health has a 12-month low of $77.21 and a 12-month high of $204.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96. The stock has a market capitalization of $1.29 billion, a PE ratio of 7.39 and a beta of 0.24. The firm's fifty day moving average price is $168.99 and its 200 day moving average price is $131.92.
Nutex Health (NASDAQ:NUTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $9.38 earnings per share for the quarter, topping the consensus estimate of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The company had revenue of $210.75 million during the quarter, compared to the consensus estimate of $215.03 million. As a group, research analysts expect that Nutex Health will post 30.11 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Kilter Group LLC acquired a new stake in Nutex Health in the second quarter worth approximately $27,000. Islay Capital Management LLC bought a new position in Nutex Health during the 4th quarter valued at $34,000. Allworth Financial LP acquired a new position in Nutex Health in the 2nd quarter worth approximately $35,000. BNP Paribas Financial Markets boosted its stake in Nutex Health by 966.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company's stock worth $40,000 after purchasing an additional 290 shares during the period. Finally, Royal Bank of Canada grew its position in Nutex Health by 752.4% during the 4th quarter. Royal Bank of Canada now owns 358 shares of the company's stock worth $59,000 after purchasing an additional 316 shares in the last quarter. Institutional investors and hedge funds own 5.32% of the company's stock.
About Nutex Health
(
Get Free Report)
Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.
The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.